ES2661844T3 - Actividad anticonvulsiva de sesquiterpenoides de bisaboleno aislados de aceite de cúrcuma - Google Patents
Actividad anticonvulsiva de sesquiterpenoides de bisaboleno aislados de aceite de cúrcuma Download PDFInfo
- Publication number
- ES2661844T3 ES2661844T3 ES12735494.2T ES12735494T ES2661844T3 ES 2661844 T3 ES2661844 T3 ES 2661844T3 ES 12735494 T ES12735494 T ES 12735494T ES 2661844 T3 ES2661844 T3 ES 2661844T3
- Authority
- ES
- Spain
- Prior art keywords
- turmerona
- ptz
- turmeric
- anticonvulsant
- turmeric oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000001961 anticonvulsive agent Substances 0.000 title claims abstract description 65
- 239000010681 turmeric oil Substances 0.000 title claims abstract description 65
- 229930003493 bisabolene Natural products 0.000 title claims abstract description 40
- XBGUIVFBMBVUEG-UHFFFAOYSA-N 1-methyl-4-(1,5-dimethyl-4-hexenylidene)-1-cyclohexene Chemical compound CC(C)=CCCC(C)=C1CCC(C)=CC1 XBGUIVFBMBVUEG-UHFFFAOYSA-N 0.000 title claims abstract description 39
- YHBUQBJHSRGZNF-HNNXBMFYSA-N alpha-bisabolene Natural products CC(C)=CCC=C(C)[C@@H]1CCC(C)=CC1 YHBUQBJHSRGZNF-HNNXBMFYSA-N 0.000 title claims abstract description 39
- 230000001773 anti-convulsant effect Effects 0.000 title description 49
- 230000000694 effects Effects 0.000 title description 46
- 229960003965 antiepileptics Drugs 0.000 title description 40
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 42
- 238000011282 treatment Methods 0.000 claims abstract description 31
- 229940125681 anticonvulsant agent Drugs 0.000 claims abstract description 23
- 206010015037 epilepsy Diseases 0.000 claims abstract description 22
- 206010010904 Convulsion Diseases 0.000 description 74
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 71
- 241000252212 Danio rerio Species 0.000 description 46
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 43
- 241000699670 Mus sp. Species 0.000 description 28
- 150000001875 compounds Chemical class 0.000 description 25
- 235000003373 curcuma longa Nutrition 0.000 description 25
- 238000012360 testing method Methods 0.000 description 24
- 235000003392 Curcuma domestica Nutrition 0.000 description 22
- 235000013976 turmeric Nutrition 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 235000012754 curcumin Nutrition 0.000 description 17
- 229940109262 curcumin Drugs 0.000 description 17
- 239000004148 curcumin Substances 0.000 description 17
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 14
- 241000196324 Embryophyta Species 0.000 description 13
- 239000000470 constituent Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000006399 behavior Effects 0.000 description 11
- 210000003169 central nervous system Anatomy 0.000 description 11
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 11
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 11
- 229960003529 diazepam Drugs 0.000 description 11
- 230000008602 contraction Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 210000001161 mammalian embryo Anatomy 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 208000015122 neurodegenerative disease Diseases 0.000 description 8
- 229960002036 phenytoin Drugs 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 230000001256 tonic effect Effects 0.000 description 8
- 235000014375 Curcuma Nutrition 0.000 description 7
- 210000003141 lower extremity Anatomy 0.000 description 7
- 229940084026 sodium valproate Drugs 0.000 description 7
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 7
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- JIJQKFPGBBEJNF-KBPBESRZSA-N Curlone Natural products CC(C)=CC(=O)C[C@H](C)[C@@H]1CCC(=C)C=C1 JIJQKFPGBBEJNF-KBPBESRZSA-N 0.000 description 6
- 208000037158 Partial Epilepsies Diseases 0.000 description 6
- 206010061334 Partial seizures Diseases 0.000 description 6
- XOCANRBEOZQNAQ-KBPBESRZSA-N alpha-turmerone Natural products O=C(/C=C(\C)/C)C[C@H](C)[C@H]1C=CC(C)=CC1 XOCANRBEOZQNAQ-KBPBESRZSA-N 0.000 description 6
- JIJQKFPGBBEJNF-UHFFFAOYSA-N curlone Chemical compound CC(C)=CC(=O)CC(C)C1CCC(=C)C=C1 JIJQKFPGBBEJNF-UHFFFAOYSA-N 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 230000002151 myoclonic effect Effects 0.000 description 6
- 231100000161 signs of toxicity Toxicity 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001364 upper extremity Anatomy 0.000 description 6
- 208000037012 Psychomotor seizures Diseases 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 201000007186 focal epilepsy Diseases 0.000 description 5
- 230000003137 locomotive effect Effects 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000020925 Bipolar disease Diseases 0.000 description 4
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000001418 larval effect Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 208000019022 Mood disease Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- HJTVQHVGMGKONQ-LUZURFALSA-N demethoxycurcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000401 methanolic extract Substances 0.000 description 3
- 230000004973 motor coordination Effects 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 3
- 230000000270 postfertilization Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000216 proconvulsive effect Effects 0.000 description 3
- 238000011808 rodent model Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 235000020240 turmeric extract Nutrition 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 102100033639 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 206010016173 Fall Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 241000234299 Zingiberaceae Species 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 2
- 150000002553 bisabolene derivatives Chemical class 0.000 description 2
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000013409 condiments Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 2
- 230000006742 locomotor activity Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 2
- 229960005152 pentetrazol Drugs 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- -1 small molecule compounds Chemical class 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 1
- ICDNYWJQGWNLFP-VXGBXAGGSA-N (2S)-2-[(R)-(2-chlorophenyl)-hydroxymethyl]-3-methoxy-2H-furan-5-one Chemical compound COC1=CC(=O)O[C@H]1[C@H](O)C1=CC=CC=C1Cl ICDNYWJQGWNLFP-VXGBXAGGSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010003628 Atonic seizures Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000033001 Complex partial seizures Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 229930153442 Curcuminoid Natural products 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 240000005546 Piper methysticum Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010040703 Simple partial seizures Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000028311 absence seizure Diseases 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 230000002026 carminative effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000008579 epileptogenesis Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000003371 gabaergic effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- 230000026779 larval behavior Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229950009284 losigamone Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000238 one-dimensional nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000002436 one-dimensional nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036977 tonic contraction Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940072040 tricaine Drugs 0.000 description 1
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000002495 two-dimensional nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229940109566 valproic acid 300 mg Drugs 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201111319 | 2011-07-04 | ||
| GBGB1111319.8A GB201111319D0 (en) | 2011-07-04 | 2011-07-04 | Anticonvulsant activity of tumeric oil and bisabolene sesquiterpenoids of curcuma longa |
| PCT/EP2012/063027 WO2013004740A1 (en) | 2011-07-04 | 2012-07-04 | Anticonvulsant activity of turmeric oil and bisabolene sesquiterpenoids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2661844T3 true ES2661844T3 (es) | 2018-04-04 |
Family
ID=44512006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12735494.2T Active ES2661844T3 (es) | 2011-07-04 | 2012-07-04 | Actividad anticonvulsiva de sesquiterpenoides de bisaboleno aislados de aceite de cúrcuma |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9782361B2 (enExample) |
| EP (1) | EP2729138B8 (enExample) |
| JP (1) | JP6090867B2 (enExample) |
| ES (1) | ES2661844T3 (enExample) |
| GB (1) | GB201111319D0 (enExample) |
| IN (1) | IN2013DN11328A (enExample) |
| WO (1) | WO2013004740A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101517843B1 (ko) | 2013-09-30 | 2015-05-08 | 한국인스팜(주) | 울금 비극성용매 가용 추출물 또는 이로부터 분리된 아로매틱-튜메론을 유효성분으로 함유하는 스트레스관련 질환의 치료 및 예방을 위한 조성물 |
| JP6773361B2 (ja) * | 2015-04-09 | 2020-10-21 | ハウスウェルネスフーズ株式会社 | 気分状態改善剤 |
| JP6883845B2 (ja) * | 2017-03-17 | 2021-06-09 | 学校法人早稲田大学 | アストロサイト分化促進用組成物 |
| US12295920B2 (en) | 2018-06-29 | 2025-05-13 | House Wellness Foods Corporation | Composition for treatment, prevention, or amelioration of Alzheimer's disease, a composition for suppression of brain nerve cell death, a composition for suppression of microglia activation induced by amyloid β peptide, and a composition for suppression of PGE2, TNF-α, or IL-1β production induced by amyloid βpeptide |
| CN110721175A (zh) * | 2018-07-17 | 2020-01-24 | 文小燕 | 姜黄提取物在制备治疗癫痫的药物中的用途 |
| FR3098396B1 (fr) * | 2019-07-10 | 2022-07-29 | Indigo Therapeutics | Composition pour le traitement des troubles des émotions |
| CN113759007B (zh) * | 2020-08-25 | 2023-03-21 | 北京康仁堂药业有限公司 | 一种广西莪术的质量控制方法 |
| US20250195601A1 (en) * | 2023-12-18 | 2025-06-19 | Universidad De Cuenca | Turmeric oil essential-oil bisabolene sesquiterpenoids in the treatment of non-neurodegenerative diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003051380A2 (en) | 2001-12-14 | 2003-06-26 | Council Of Scientific And Industrial Research | Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders |
| US20040254146A1 (en) * | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
| JP2004331539A (ja) * | 2003-05-06 | 2004-11-25 | Maruzen Pharmaceut Co Ltd | 肝臓疾患予防治療剤及び肝臓疾患予防治療用飲食物 |
| US20080193573A1 (en) * | 2006-03-17 | 2008-08-14 | Gow Robert T | Extracts and methods comprising curcuma species |
| CN101199833B (zh) * | 2007-12-21 | 2011-03-16 | 北京中科雍和医药技术有限公司 | 一种缓解关节炎疼痛的复方精油 |
| TW201019949A (en) | 2008-10-16 | 2010-06-01 | Herbalscience Group Llc | Extracts of curcuma and methods of use thereof |
| EP2458983B1 (en) * | 2009-07-31 | 2015-07-08 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| WO2011080090A1 (en) | 2009-12-31 | 2011-07-07 | Arcelik Anonim Sirketi | A dishwasher comprising a microfilter |
| AU2011228689A1 (en) * | 2010-03-15 | 2012-09-27 | Laila Nutraceuticals | Boswellia oil, its fractions and compositions for enhancing brain function |
| EP2555787B1 (en) * | 2010-04-05 | 2017-11-08 | Benny Antony | Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof |
-
2011
- 2011-07-04 GB GBGB1111319.8A patent/GB201111319D0/en not_active Ceased
-
2012
- 2012-07-04 WO PCT/EP2012/063027 patent/WO2013004740A1/en not_active Ceased
- 2012-07-04 EP EP12735494.2A patent/EP2729138B8/en active Active
- 2012-07-04 IN IN11328DEN2013 patent/IN2013DN11328A/en unknown
- 2012-07-04 ES ES12735494.2T patent/ES2661844T3/es active Active
- 2012-07-04 JP JP2014517788A patent/JP6090867B2/ja active Active
- 2012-07-04 US US14/130,702 patent/US9782361B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP6090867B2 (ja) | 2017-03-08 |
| WO2013004740A1 (en) | 2013-01-10 |
| US20140243420A1 (en) | 2014-08-28 |
| EP2729138B8 (en) | 2018-02-28 |
| JP2014518241A (ja) | 2014-07-28 |
| IN2013DN11328A (enExample) | 2015-05-15 |
| EP2729138A1 (en) | 2014-05-14 |
| GB201111319D0 (en) | 2011-08-17 |
| US9782361B2 (en) | 2017-10-10 |
| EP2729138B1 (en) | 2017-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2661844T3 (es) | Actividad anticonvulsiva de sesquiterpenoides de bisaboleno aislados de aceite de cúrcuma | |
| Orellana-Paucar et al. | Anticonvulsant activity of bisabolene sesquiterpenoids of Curcuma longa in zebrafish and mouse seizure models | |
| ES2992665T3 (en) | 6-hydroxy cannabidiol for use as a medicament | |
| Wijeweera et al. | Evaluation of anxiolytic properties of Gotukola–(Centella asiatica) extracts and asiaticoside in rat behavioral models | |
| Wang et al. | Antinociceptive and anti-inflammatory activities of extract and two isolated flavonoids of Carthamus tinctorius L | |
| Franchin et al. | Geopropolis from Melipona scutellaris decreases the mechanical inflammatory hypernociception by inhibiting the production of IL-1β and TNF-α | |
| Mengarda et al. | Antiparasitic activity of piplartine (piperlongumine) in a mouse model of schistosomiasis | |
| Dhingra et al. | Inhibition of MAO and GABA: probable mechanisms for antidepressant-like activity of Nardostachys jatamansi DC. in mice | |
| Ferlemi et al. | Rosemary tea consumption results to anxiolytic-and anti-depressant-like behavior of adult male mice and inhibits all cerebral area and liver cholinesterase activity; phytochemical investigation and in silico studies | |
| Fumia et al. | Role of nutraceuticals on neurodegenerative diseases: Neuroprotective and immunomodulant activity | |
| Khoshnam et al. | Vanillic acid attenuates effects of transient bilateral common carotid occlusion and reperfusion in rats | |
| Nabavi et al. | The water extract of tutsan (Hypericum androsaemum L.) red berries exerts antidepressive-like effects and in vivo antioxidant activity in a mouse model of post-stroke depression | |
| Durg et al. | Antipsychotic activity of embelin isolated from Embelia ribes: A preliminary study | |
| Fongang et al. | Antinociceptive and anti-inflammatory effects of the methanolic stem bark extract of Antrocaryon klaineanum Pierre (Anacardiaceae) in mice and rat | |
| EP3019162B1 (en) | Dan shen extracts and compounds | |
| Moussavi et al. | Inhibition of seizure-like paroxysms and toxicity effects of Securidaca longepedunculata extracts and constituents in zebrafish Danio rerio | |
| Sałaga et al. | Neuropharmacological characterization of the oneirogenic Mexican plant Calea zacatechichi aqueous extract in mice | |
| Holowacz et al. | Anti-diarrheal and anti-nociceptive effects of a hydroethanolic leaf extract of walnut in rats | |
| Shareef et al. | Neuropharmacological screening of essential oil from oleo gum resin of Gardenia lucida Roxb | |
| US10780139B1 (en) | Hypericum revolutum extract as a vasodilator | |
| Bertoncello et al. | Berberine and hesperidin prevent the memory consolidation impairment induced by pentylenetetrazole in zebrafish | |
| Gangwar et al. | Study on activity of alcoholic extract of glands and hairs of fruits of Mallotus philippinensis in murine cestodal infection model | |
| Anawal et al. | Neuroprotective activity of polyherbal formulation on colchicine induced alzheimer's disease in rat model | |
| Hayta et al. | Neuroprotective effects of Sideritis trojana essential oil in AlCl3-induced amnesic rats | |
| Mahmood et al. | Evaluation of neuropharmacological activity of Cardiospermum halicacabum (Linn) leaf extract |